Evidence map›Paper›PMID 40950006›Full record

ArticlebioRxiv : the preprint server for biology2025

Differential effects of sodium on agonist-induced conformational transitions and signaling at μ and κ opioid receptors.

Bram Kuijer, Camryn J Fulton, Talia L Albert, Paloma M Knobloch, Jing Wang, Brian E Krumm, Tao Che, Balazs R Varga, Susruta Majumdar, Vsevolod Katritch and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Bram KuijerDepartment of Pharmacology and NIMH Psychoactive Drug Screening Program, UNC Chapel Hill Medical School, Chapel Hill, NC 27514.
Camryn J FultonDepartment of Pharmacology and NIMH Psychoactive Drug Screening Program, UNC Chapel Hill Medical School, Chapel Hill, NC 27514.
Talia L AlbertDepartment of Pharmacology and NIMH Psychoactive Drug Screening Program, UNC Chapel Hill Medical School, Chapel Hill, NC 27514.
Paloma M KnoblochDepartment of Pharmacology and NIMH Psychoactive Drug Screening Program, UNC Chapel Hill Medical School, Chapel Hill, NC 27514.
Jing WangDepartment of Pharmacology and NIMH Psychoactive Drug Screening Program, UNC Chapel Hill Medical School, Chapel Hill, NC 27514.
Brian E KrummDepartment of Pharmacology and NIMH Psychoactive Drug Screening Program, UNC Chapel Hill Medical School, Chapel Hill, NC 27514.
Tao CheCenter for Clinical Pharmacology, Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, USA.
Balazs R VargaCenter for Clinical Pharmacology, Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, USA.
Susruta MajumdarCenter for Clinical Pharmacology, Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, USA.
Vsevolod KatritchDepartments of Quantitative and Computational Biology, Chemistry, and Pharmacology and Pharmaceutical Sciences, USC Dornsife College of Arts and Sciences, Los Angeles, CA.
Ryan H GumpperDivision of Medicinal Chemistry and Chemical Biology, UNC Eshelman School of Pharmacy, Chapel Hill, NC 27514.
Terry KenakinDepartment of Pharmacology and NIMH Psychoactive Drug Screening Program, UNC Chapel Hill Medical School, Chapel Hill, NC 27514.
Xi-Ping HuangDepartment of Pharmacology and NIMH Psychoactive Drug Screening Program, UNC Chapel Hill Medical School, Chapel Hill, NC 27514.
Bryan L RothDepartment of Pharmacology and NIMH Psychoactive Drug Screening Program, UNC Chapel Hill Medical School, Chapel Hill, NC 27514.

Funding

Molecular Details of Psychoactive Drug ActionsR01MH112205 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Bryan L. Roth, Brian K Shoichet · 2017 to 2026
$6.1M
Mechanistic insights into LSD actions at 5-HT2A serotonin receptorsR37DA045657 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Bryan L. Roth · 2018 to 2026
$5.8M
Validation of Therapeutic Target and Underlying BiologyU19NS138975 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AUBE, JEFFREY, SCHERRER, GREGORY · 2024 to 2024
$4.6M
Targeting the allosteric sodium site with novel probes for delta opioid receptorR01DA057790 · NIDA · WASHINGTON UNIVERSITY · PI Tao Che, VSEVOLOD KATRITCH · 2023 to 2026
$2.6M
Efficacy and signaling modulation by targeting the sodium site at mu opioid receptorR01DA059978 · NIDA · WASHINGTON UNIVERSITY · PI Susruta Majumdar · 2024 to 2026
$1.8M
NIDA NIH HHS R01 DA057790NIDA NIH HHS R01 DA059978NIDA NIH HHS R37 DA045657NIMH NIH HHS R01 MH112205NINDS NIH HHS U19 NS138975
6 · The paper itself

Abstract

Sodium ions are classically conceptualized as negative allosteric modulators for G protein coupled receptors (GPCRs), although there have been reports of either positive allosteric modulation or no effect of sodium on GPCR function. Here we identified opposing actions of sodium on the μ and κ opioid receptors. We utilized a variety of methods including radioligand binding, real-time conformational monitoring of transitions using bioluminescence resonance energy transfer and signaling assays using the TRUPATH resource. At the μ receptors, sodium behaved as a negative allosteric modulator of binding, conformational transitions and signaling. Intriguingly, bitopic μ agonists were unaffected by sodium concentrations. By contrast, at the κ opioid receptor sodium negatively modulated agonist binding and positively modulated conformational transitions and signaling. Taken together, these findings support the notion that the differential sensitivities to sodium concentrations will result in opposing effects on cell surface and intracellular signaling.

Identifiers

PMID40950006
PMCPMC12424796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.